Resonance Health: Receives HepaFat FDA clearance

  • Resonance Health (RHT) has received a key clearance for its HepaFat product from the U.S. Food and Drug Administration (FDA)
  • The product essentially works as a non-invasive medical device which measures the volume fraction of fat in liver tissue
  • This approval from the FDA will also allow Resonance to market HepaFat for commercial distribution in the U.S.
  • The company’s CEO has labeled the 501(k) clearance an “outstanding result”
  • Company CEO Alison Laws also said the clearance is an important milestone for Resonance
  • Shareholders agree, with Resonance shares shooting up 41.9 percent and trading at 22 cents each
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

Experian Launches Credit Score App in ChatGPT, Enhancing Financial Access

New tool enables users to check credit scores effortlessly via ChatGPT.Highlights: Experian's app allows users to check credit...

US Senate Passes Bill Banning Issuance of CBDCs

Legislation aims to restrict the development of digital currencies by the Federal Reserve.Highlights: The US Senate approved a...

Truist Expands Open Banking Offerings with Plaid Partnership

Collaboration aims to enhance customer access to financial services.Highlights: Truist collaborates with Plaid for open banking expansion.The partnership...

UK’s National Fraud Database Reports 444,000 Fraud Cases in 2025

Cifas reveals a significant rise in reported fraud incidents across the UK.Highlights: Cifas reported 444,000 fraud cases in...